IP Library Granted Patent US 11,078,300
Granted Patent B2
US 11,078,300 · App. 16/802,377 · Granted Aug 3, 2021

Circular tandem repeat proteins

Inventors: Philip Bradley (Seattle, WA); Barry L. Stoddard (Seattle, WA)
Assignee: Fred Hutchinson Cancer Research Center
C07K19/00C07K7/08C07K14/00C07K14/001C07K14/44C07K14/47C07K14/55C12N15/62A61K38/00C07K2319/00C07K2319/21C07K2319/50C07K2319/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,078,300
App. No.
16/802,377
Granted
Aug 3, 2021
Kind
B2
Abstract

Circular handed alpha-helical repeat proteins are described. The repeat proteins have a number of uses as scaffolds for geometrically precise, arrayed presentation of cell-signaling or immune-related protein and peptide epitopes, as well as numerous other therapeutic, diagnostic, and nanotechnological uses.

Claims (33)

1. A protein having the formula: (a-b-x-y) n wherein

a and x represent linker sequences;

b represents an amino acid sequence that forms an alpha (α) helix;

y represents an amino acid sequence that forms a second α helix;

n=3, 6, 9, 12, or 24;

the protein is handed, and

the N- and C-termini of the protein create a circular architecture.

2. The protein of claim 1 , wherein the linker sequences are flexible linker sequences.

3. The protein of claim 2 , wherein the flexible linker sequences are GBB linker sequences.

4. The protein of claim 3 , wherein the GBB linker sequences are selected from GKS; GIT; GTT; GYS; GDK; GDE; NDK; GDR; GDL; and GIS.

5. The protein of claim 1 , wherein the protein is left-handed.

6. The protein of claim 1 , wherein b and y have 100% sequence identity.

7. The protein of claim 1 , wherein b and y have at least 98% sequence identity.

8. The protein of claim 1 , wherein b and y are selected from the sequences as set forth in SEQ ID NOs. 1-50; 124-129; 139; 140; 146; or 147.

9. A protein of claim 1 , wherein each (a-b-x-y) unit that is not an N-terminal or C-terminal (a-b-x-y) unit has 100% sequence identity with an adjacent (a-b-x-y) unit.

10. A protein of claim 1 , wherein each (a-b-x-y) unit has at least 95% sequence identity with an adjacent (a-b-x-y) unit.

11. The protein of claim 1 , comprising a sequence selected from the sequences as set forth in SEQ ID NOs. 51-70; 117-123; 135-138 or 145.

12. A circular, handed protein comprising at least three α-helical structures wherein each α-helical structure comprises an outer α helix and an inner α helix joined by a flexible linker and wherein each α-helical structure has at least 95% sequence identity with an adjacent α-helical structure.

13. The circular, handed protein of claim 12 , wherein the flexible linker is a GBB linker.

14. The circular, handed protein of claim 13 , wherein the GBB linker is a sequence selected from GKS; GIT; GTT; GYS; GDK; GDE; NDK; GDR; GDL; and GIS.

15. The circular, handed protein of claim 12 , further comprising at least two functional domains wherein each functional domain is inserted into the sequence of the protein between an outer α helix of the protein and an adjacent inner α helix of the protein and wherein at least one of the functional domains is selected from a cytokine, a Notch ligand, an immunogenic peptide, a peptide adjuvant, a single-chain class I MHC domain, or a small molecule ligand binding domain.

16. A protein having the formula: (d-a-b-x-y) n ; (a-d-b-x-y) n ; (a-b-d-x-y) n ; (a-b-x-d-y) n or (a-b-x-y-d) n wherein

a and x represent linker sequences;

b represents an amino acid sequence that forms an alpha (α) helix;

y represents an amino acid sequence that forms a second α helix;

d represents a functional domain;

n=3, 6, 9, 12, or 24;

the protein is handed, and

the N- and C-termini of the protein create a circular architecture.

17. The protein of claim 16 , wherein the functional domain comprises a cytokine, a Notch ligand, an immunogenic peptide, a peptide adjuvant, a single-chain class I MHC domain, or a small molecule ligand binding domain.

18. The protein of claim 16 , wherein the functional domain comprises SH2, SH3, IL-2, IL-3, IL-17c, single-chain MHC, the extracellular domain of the Delta-1 Notch protein ligand, Protein L, a protein having the sequence set forth in SEQ ID NO: 116, or a protein having the sequence set forth in SEQ ID NO: 115.

19. The protein of claim 16 , wherein the linker sequences are flexible linker sequences.

20. The protein of claim 16 , wherein b and y have at least 98% sequence identity.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jun 22, 2022
From: FRED HUTCHINSON CANCER RESEARCH CENTER; SEATTLE CANCER CARE ALLIANCE
To: FRED HUTCHINSON CANCER CENTER
Reel/Frame 060434/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 11, 2020
From: BRADLEY, PHILIP; STODDARD, BARRY L.
To: FRED HUTCHINSON CANCER RESEARCH CENTER
Reel/Frame 052083/0510 →
Continuity (3)
Continuation 15780397
Provisional Application 62262146 · Dec 2, 2015
Related Publication 20200190220A1 · Jun 18, 2020